Your browser doesn't support javascript.
loading
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Vogelzang, Nicholas J; Fizazi, Karim; Burke, John M; De Wit, Ronald; Bellmunt, Joaquim; Hutson, Thomas E; Crane, Edward; Berry, William R; Doner, Kevin; Hainsworth, John D; Wiechno, Pawel J; Liu, Kejian; Waldman, Michelle F; Gandhi, Anita; Barton, Debora; Jungnelius, Ulf; Fandi, Abderrahim; Sternberg, Cora N; Petrylak, Daniel P.
Afiliación
  • Vogelzang NJ; US Oncology Research, Houston, TX, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. Electronic address: Nicholas.Vogelzang@usoncology.com.
  • Fizazi K; Institut Gustave Roussy, Department of Cancer Medicine, University of Paris Sud, Villejuif, France.
  • Burke JM; US Oncology Research, Houston, TX, USA; Rocky Mountain Cancer Centers, Aurora, CO, USA.
  • De Wit R; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Bellmunt J; University Hospital del Mar-IMIM, Barcelona, Spain; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Hutson TE; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
  • Crane E; Oncology Hematology Care, Inc., Cincinnati, OH, USA.
  • Berry WR; US Oncology, Cancer Centers of North Carolina, Raleigh, NC, USA.
  • Doner K; Texas Oncology, Austin, TX, USA.
  • Hainsworth JD; Sarah Cannon Research Institute, Nashville, TN, USA.
  • Wiechno PJ; Department of Uro-Oncology, Centrum Onkologii - Instytut im Marii Sklodowskiej-Curie, Warsaw, Poland.
  • Liu K; Celgene Corporation, Summit, NJ, USA.
  • Waldman MF; Celgene Corporation, Summit, NJ, USA.
  • Gandhi A; Celgene Corporation, Summit, NJ, USA.
  • Barton D; Celgene Corporation, Summit, NJ, USA.
  • Jungnelius U; Celgene Corporation, Summit, NJ, USA.
  • Fandi A; Celgene Corporation, Summit, NJ, USA.
  • Sternberg CN; San Camillo and Forlanini Hospitals, Department of Medical Oncology, Rome, Italy.
  • Petrylak DP; Yale Cancer Center, Department of Medicine Division of Oncology, New Haven, CT, USA.
Eur Urol ; 71(2): 168-171, 2017 02.
Article en En | MEDLINE | ID: mdl-27522164
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Taxoides / Neoplasias de la Próstata Resistentes a la Castración / Células Neoplásicas Circulantes Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Eur Urol Año: 2017 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Taxoides / Neoplasias de la Próstata Resistentes a la Castración / Células Neoplásicas Circulantes Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Eur Urol Año: 2017 Tipo del documento: Article